

WEST**End of Result Set**☐ **Generate Collection**

L2: Entry 1 of 1

File: DWPI

Mar 17, 1999

DERWENT-ACC-NO: 1997-448319

DERWENT-WEEK: 199930

COPYRIGHT 2000 DERWENT INFORMATION LTD

TITLE: Antiviral, anti-neoplastic, antibacterial or antifungal compositions -
comprise leukotriene B4 agent and carrier, optionally with additional antiviral
agent(s)

INVENTOR: BORGEAT, P; GOSSELIN, J

PATENT-ASSIGNEE:

ASSIGNEE

VIROCELL INC

CODE

VIRON

BEST AVAILABLE COPY

PRIORITY-DATA:

1997US-0798937

February 11, 1997

1996US-0602059

February 15, 1996

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
CN 1211184 A	March 17, 1999	N/A	000	A61K031/557
WO 9729751 A1	August 21, 1997	E	055	A61K031/557
AU 9715867 A	September 2, 1997	N/A	000	A61K031/557
US 5789441 A	August 4, 1998	N/A	000	A61K031/20
EP 881900 A1	December 9, 1998	E	000	A61K031/557

DESIGNATED-STATES: AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB
GE HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT
RO RU SD SE SG SI SK TJ TM TR TT UA UG UZ VN AT BE CH DE DK EA ES FI FR GB GR IE
IT KE LS LU MC MW NL OA PT SD SE SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LI LU
MC NL PT SE

CITED-DOCUMENTS:4.Jnl.Ref; EP 381823

APPLICATION-DATA:

PUB-NO	APPL-DATE	APPL-NO	APPL-DESCRIPTOR
CN 1211184A	February 12, 1997	1997CN-0192276	N/A
WO 9729751A1	February 12, 1997	1997WO-CA00099	N/A
AU 9715867A	February 12, 1997	1997AU-0015867	N/A
AU 9715867A	N/A	WO 9729751	Based on
US 5789441A	February 15, 1996	1996US-0602059	CIP of
US 5789441A	February 11, 1997	1997US-0798937	N/A
EP 881900A1	February 12, 1997	1997EP-0902124	N/A
EP 881900A1	February 12, 1997	1997WO-CA00099	N/A
EP 881900A1	N/A	WO 9729751	Based on

INT-CL (IPC): A61K 31/20; A61K 31/23; A61K 31/557; C07C 69/587

ABSTRACTED-PUB-NO: US 5789441A
BASIC-ABSTRACT:

Antiviral compositions (I) and anti-neoplastic, antibacterial or antifungal compositions (II), comprising a pharmacologically acceptable, therapeutically effective amount of a leukotriene B4 (LTB4) agent and a carrier, are new.

Also claimed is the use of a LTB4 agent for prophylaxis or treatment of viral infections, cancer induced by oncogene viruses, and cancer, bacterial or fungal infections in humans and animals.

USE - The viral infections treated are caused by DNA viruses, RNA viruses or retroviridae. The DNA virus is parvoviridae, papovaviridae, adenoviridae, herpesviridae (especially Epstein-Barr virus (EBV), Herpes Simplex virus (HSV)-1, HSV-2, CMV, VZV, human Herpes virus (HHV)-6, HHV-7 or HHV-8), poxviridae or hepadnaviridae. The RNA virus is picornaviridae, togarviridae, orthomyxoviridae, paramyxoviridae, coronaviridae, reoviridae, oncornaviridae or filoviridae.

The virus may also be a bovine diarrhoea virus, a porcine enterovirus, a paramyxoviridae or a bovine respiratory syncytical virus.

The retroviridae is HIV-1 or HIV-2.

For LTB4, administration is in sufficient doses to obtain an effective peak or steady-state concentration of 1-1000nM (usually 200nM) in plasma.

ABSTRACTED-PUB-NO: WO 9729751A
EQUIVALENT-ABSTRACTS:

BEST AVAILABLE COPY

Antiviral compositions (I) and anti-neoplastic, antibacterial or antifungal compositions (II), comprising a pharmacologically acceptable, therapeutically effective amount of a leukotriene B4 (LTB4) agent and a carrier, are new.

Also claimed is the use of a LTB4 agent for prophylaxis or treatment of viral infections, cancer induced by oncogene viruses, and cancer, bacterial or fungal infections in humans and animals.

USE - The viral infections treated are caused by DNA viruses, RNA viruses or retroviridae. The DNA virus is parvoviridae, papovaviridae, adenoviridae, herpesviridae (especially Epstein-Barr virus (EBV), Herpes Simplex virus (HSV)-1, HSV-2, CMV, VZV, human Herpes virus (HHV)-6, HHV-7 or HHV-8), poxviridae or hepadnaviridae. The RNA virus is picornaviridae, togarviridae, orthomyxoviridae, paramyxoviridae, coronaviridae, reoviridae, oncornaviridae or filoviridae.

The virus may also be a bovine diarrhoea virus, a porcine enterovirus, a paramyxoviridae or a bovine respiratory syncytical virus.

The retroviridae is HIV-1 or HIV-2.

For LTB4, administration is in sufficient doses to obtain an effective peak or steady-state concentration of 1-1000nM (usually 200nM) in plasma.

CHOSEN-DRAWING: Dwg.0/8

DERWENT-CLASS: B05 C03
CPI-CODES: B04-H03F; C04-H03F; B07-A03; C07-A03; B07-A04; C07-A04; B10-C04D;
C10-C04D; B14-A01; C14-A01; B14-A02; C14-A02; B14-A04; C14-A04; B14-H01; C14-H01;